Re-Listing Still The Best Option For Chinese Life Sciences Firms?
This article was originally published in PharmAsia News
Executive Summary
There has been a trend for US-listed Chinese life sciences and health care companies to go private and eventually relist back home. But this process is not only becoming increasingly cumbersome, there is a lot more to worry about than just getting a higher valuation, insiders tell PharmAsia News.